Pharmabiz1h
Late-breaking data reinforce long-term benefits of Abbott's Amplatzer Amulet device for people with atrial fibrillation at risk of stroke
Abbott Park, Illinois Wednesday, November 20, 2024, 13:00 Hrs [IST] ...
Digi Times5h
VitalTracer's path to innovation: Revolutionizing remote patient monitoring
In 2010, Azadeh Dastmalchi's journey toward transforming healthcare began with a personal challenge. Her father's aversion to ...
FierceBiotech17h
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
MassDevice18h
Abbott reports positive Amplatzer Amulet data in head-to-head trial with Boston Scientific’s Watchman
Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.
Buy Rating on Boston Scientific: WATCHMAN Product’s Expanding Market Potential and Revenue Growth
In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...
Boston Scientific’s WATCHMAN FLX: Poised for Growth with New Trial Results and Reimbursement Code
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...
The 8 next big technologies in health for 2024
Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...
Pharmabiz21h
Boston Scientific WATCHMAN FLX LAAC device demonstrates superior bleeding risk reduction to OAC following a cardiac ablation in OPTION clinical trial
Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...
GlobalData on MSN23h
Abbott’s Amplatzer Amulet shows promise in atrial fibrillation trial
Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...